Brigatinib Tablet Market
Report ID: SQMIG35I3657
Report ID: SQMIG35I3657
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3657 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
144
|Figures:
78
Global Brigatinib Tablet Market size was valued at USD 780.0 Million in 2024 and is poised to grow from USD 843.18 Million in 2025 to USD 1572.27 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
The global brigatinib tablet market centers on brigatinib, an oral ALK inhibitor approved for treatment‑resistant NSCLC and increasingly for ALK‑positive metastatic disease. Its primary driver stems from the unmet clinical need for effective second‑line options after failure of first‑generation agents like crizotinib, a gap that clinicians have filled by adopting brigatinib for its superior central‑brain penetration and longer progression‑free survival. Since FDA approval in 2017, prescriptions have accelerated globally, especially after the 2020 ALTA Phase III trial showed a 45 % reduction in intracranial progression versus alectinib, leading insurers to broaden coverage and hospitals to embed brigatinib in NSCLC pathways overall today.
Building on the established clinical need, a second key factor propelling market expansion is the rising prevalence of ALK‑rearranged lung cancer in younger, non‑smoking populations, which fuels demand for oral therapies that can be managed outside hospital settings. Pharma firms are forming alliances with generic makers to secure cost‑effective supply chains, lowering price barriers and encouraging adoption in emerging markets like China and Brazil. Real‑world data from US Medicare show a 22 % survival gain for patients switching to brigatinib after crizotinib failure, reinforcing its value and prompting health systems to negotiate volume rebates across the industry and sustainable pricing models.
How is AI-driven Patient Adherence Monitoring Influencing The Global Brigatinib Tablet Market?
AI-driven patient adherence monitoring is playing a growing supportive role in shaping the Brigatinib tablet market, as AI algorithms are increasingly used to personalize treatment plans based on patient data, helping increase patient adherence and outcomes, which in turn supports market growth. Since Brigatinib is a targeted therapy for ALK-positive non-small cell lung cancer where consistent dosing directly affects survival outcomes, tools that flag non-adherence or missed doses help sustain treatment continuity and reduce dose interruptions.
Broader digital adherence technologies, including AI-enabled monitoring platforms, mobile-based confirmation systems, and predictive intervention models, are being adopted across oncology to identify patients at risk of non-adherence and prompt timely support. This trend strengthens demand consistency for Brigatinib by improving real-world persistence rates, reinforcing manufacturers' focus on integrating digital adherence support alongside their commercial and patient-assistance strategies.
Market snapshot - (2026-2033)
Global Market Size
USD 780.0 Million
Largest Segment
180 mg
Fastest Growth
30 mg
Growth Rate
8.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global brigatinib tablet market is segmented by strength, indication, distribution channel, end user and region. Based on strength, the market is segmented into 30 mg, 90 mg and 180 mg. Based on indication, the market is segmented into ALK-Positive NSCLC and Other Oncology Indications. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Cancer Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
180 Mg dosage segment dominates because clinicians prioritize the higher dose for patients with advanced disease, offering stronger efficacy and longer progression free survival. This preference drives prescribing habits, solidifies formulary placement, and encourages manufacturers to focus production capacity on the 180 mg strength. Consequently, the market allocates the majority of revenue and inventory to this dose, reinforcing its leadership position. Consequently, hospitals drive formulary inclusion and long term therapeutic contracts, solidifying their leadership role.
However, 90 mg dosage segment emerges as the fastest growing because clinicians are increasingly using it as a step down therapy after patients achieve disease control, reducing toxicity while maintaining efficacy. This practice expands the patient pool, encourages broader adoption, and stimulates pipeline innovations that boost overall market momentum.
Hospital pharmacies segment dominates because they serve as primary procurement hubs for large health systems, integrating Brigatinib into standardized oncology treatment pathways. Their centralized purchasing power ensures consistent volume orders, and their clinical pharmacy teams provide stewardship that reinforces guideline based use. This results in deep inventory commitments, preferential pricing arrangements, and sustained demand that anchors the overall market structure. Consequently, hospitals drive formulary inclusion and long term therapeutic contracts, solidifying their leadership role.
Meanwhile, online pharmacies segment is witnessing the strongest growth because patients increasingly prefer home delivery and discreet access to specialty oncology drugs. Digital platforms simplify prior authorization, expand reach to remote clinics, and leverage telehealth partnerships that boost prescribing confidence. This convenience accelerates market penetration, creates revenue streams, and positions online channels as drivers of future expansion.
To get detailed segments analysis, Request a Free Sample Report
North America leads the global Brigatinib Tablet market due to a confluence of advanced healthcare systems, strong payer support, and early adoption of precision oncology therapies. The region benefits from a mature regulatory framework that accelerates product approvals and encourages innovative drug development. Presence of major pharmaceutical companies and research institutions fosters continuous clinical investigation and rapid integration of new treatment options. High physician awareness and patient access programs further reinforce market penetration. Additionally, robust insurance coverage and favorable reimbursement policies reduce financial barriers, enabling broader utilization across diverse patient populations. These combined factors create a fertile environment that sustains the region’s dominant position in the Brigatinib Tablet landscape. The collaborative ecosystem between academic centers and industry accelerates knowledge transfer, while digital health tools enhance patient monitoring and adherence, further solidifying market leadership.
Brigatinib Tablet Market in the United States is propelled by extensive clinical networks and a strong emphasis on personalized cancer care. Leading oncology centers actively incorporate Brigatinib into treatment protocols, supported by comprehensive insurance coverage that eases patient access. Ongoing physician education initiatives and patient advocacy groups raise awareness, while collaborative research programs with biotech firms sustain a pipeline of real‑world evidence that reinforces therapeutic confidence and contribute to sustained market growth.
Brigatinib Tablet Market in Canada benefits from a publicly funded healthcare system that prioritizes equitable access to innovative therapies. Provincial drug plans incorporate Brigatinib into formularies, enabling patients across regions to receive treatment without prohibitive out‑of‑pocket costs. Multidisciplinary tumor boards and national oncology societies champion guideline‑driven adoption, while partnerships between academic hospitals and pharmaceutical sponsors foster clinical trials that generate local evidence and support continued uptake, strengthening the overall market position.
Europe experiences rapid expansion of the Brigatinib Tablet market driven by a cohesive regulatory environment that streamlines cross‑border approvals and encourages multinational clinical collaborations. Health technology assessment bodies across the region increasingly recognize the value of targeted therapies, resulting in favorable reimbursement pathways that improve patient access. Established oncology networks and specialist centers actively integrate Brigatinib into treatment algorithms, supported by robust physician education programs and patient advocacy initiatives. The presence of leading pharmaceutical hubs and research institutions fuels continuous generation of real‑world evidence, reinforcing confidence among prescribers. Additionally, collaborative frameworks between governments, payers, and industry promote value‑based pricing models, ensuring sustainable market growth while maintaining high standards of care. The emphasis on personalized medicine also drives investment in diagnostic capabilities, enabling clinicians to identify eligible patients more efficiently. Moreover, cross‑national patient registries facilitate data sharing, further supporting evidence‑based adoption of Brigatinib across diverse healthcare settings.
Brigatinib Tablet Market in Germany is anchored by a strong network of university hospitals that serve as centers of excellence for lung cancer treatment. National reimbursement guidelines incorporate Brigatinib for eligible patients, facilitating timely access. Continuous medical education and guideline updates ensure clinicians remain informed about optimal use, while collaborative research initiatives generate robust clinical data that reinforce therapeutic confidence. Patient advocacy groups also play a pivotal role in raising awareness and supporting treatment pathways.
Brigatinib Tablet Market in the United Kingdom is experiencing the fastest growth due to proactive NHS commissioning that prioritizes innovative oncology options. Specialist cancer centers rapidly adopt Brigatinib within multidisciplinary pathways, supported by clear clinical guidelines and reimbursement mechanisms. Ongoing real‑world evidence collection through national registries enhances confidence among prescribers, while patient support programs improve adherence. Collaborative efforts between academia, industry, and health authorities further accelerate market penetration.
Brigatinib Tablet Market in France is emerging as healthcare providers integrate targeted therapies into evolving treatment protocols. The national health insurance system increasingly reimburses Brigatinib for specific indications, encouraging broader patient access. Academic oncology groups and professional societies actively disseminate clinical data, fostering physician confidence. Early‑stage collaborative studies with biotech partners generate localized evidence, while patient associations raise disease awareness, collectively supporting gradual market expansion.
Asia Pacific is strengthening its position in the Brigatinib Tablet market through a combination of expanding healthcare infrastructure, rising prevalence of targeted therapy adoption, and supportive regulatory pathways that expedite market entry. Nations within the region are investing heavily in oncology centers of excellence, enabling rapid integration of Brigatinib into clinical practice. Collaborative agreements between multinational pharmaceutical firms and local distributors enhance supply chain efficiency and broaden patient reach. Growing emphasis on precision medicine drives development of companion diagnostics, facilitating accurate patient selection. Additionally, regional academic consortia and government‑backed research initiatives generate robust clinical data, building confidence among clinicians and payers alike, thereby fostering sustainable market growth across the Asia Pacific landscape. The increasing adoption of digital health platforms also supports remote monitoring and adherence, further enhancing therapeutic outcomes. Moreover, regional policy frameworks are progressively aligning reimbursement criteria with clinical value, ensuring that patients receive timely access to Brigatinib.
Brigatinib Tablet Market in Japan is driven by a sophisticated oncology ecosystem that emphasizes early adoption of innovative therapies. National health insurance provides comprehensive coverage for Brigatinib, facilitating patient access across urban and regional hospitals. Strong collaboration between academic institutions and pharmaceutical companies accelerates clinical research, generating high‑quality evidence that supports guideline inclusion. Patient advocacy groups also contribute to awareness, while digital health initiatives improve treatment monitoring and adherence.
Brigatinib Tablet Market in South Korea benefits from a proactive regulatory environment that encourages swift approval of targeted cancer agents. Government‑supported reimbursement schemes ensure that Brigatinib is accessible to eligible patients, reducing financial barriers. Leading cancer centers incorporate the therapy into multidisciplinary protocols, backed by ongoing physician training programs. Partnerships with biotech firms foster local clinical trials, producing region‑specific data that reinforce confidence among healthcare providers.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expanding Indication Landscape
Advances In Targeted Delivery Technologies
High Cost Of Targeted Therapy
Regulatory Uncertainty In Emerging Regions
Request Free Customization of this report to help us to meet your business objectives.
The Brigatinib tablet market remains highly competitive within the broader ALK-inhibitor landscape, with Takeda holding exclusive commercialization rights while facing pressure from rivals such as alectinib, lorlatinib, crizotinib, and ceritinib, where Takeda Pharmaceutical has exclusive rights for brigatinib commercialization amidst competitors like alectinib, lorlatinib, crizotinib, and ceritinib. Product development continues through ongoing trials expanding into earlier treatment lines and immunotherapy combinations, alongside real-world evidence generation and updated safety guidance. Competitive strategy centers on clinical differentiation—particularly brain penetration and resistance-mutation coverage—alongside physician education, real-world evidence generation, and partnerships with specialty pharmacy networks to strengthen healthcare-system access. Meanwhile, emerging next-generation inhibitors and evolving regulatory requirements continue reshaping competitive dynamics across regions.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global Brigatinib tablet market is propelled primarily by the expanding indication landscape that adds new ALK‑positive and ROS1‑positive lung cancer uses, encouraging wider adoption across oncology practices. A second important driver is the integration of precision oncology, where comprehensive genomic profiling and companion diagnostics steer clinicians toward Brigatinib for mutation‑specific patients. The market remains constrained by the high cost of the targeted therapy, which leads to tougher formulary placement and reimbursement hurdles in many health systems. North America continues to dominate due to its advanced healthcare infrastructure and strong payer support, while the 180 mg strength segment commands the largest share, reflecting clinicians’ preference for the higher dose in advanced disease.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 780.0 Million |
| Market size value in 2033 | USD 1572.27 Million |
| Growth Rate | 8.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Brigatinib Tablet Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Brigatinib Tablet Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Brigatinib Tablet Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Brigatinib Tablet Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Brigatinib Tablet Market size was valued at USD 780.0 Million in 2024 and is poised to grow from USD 843.18 Million in 2025 to USD 1572.27 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
Takeda’s acquisition of ARIAD and subsequent licensing agreements with regional distributors have intensified competition, while generic manufacturers such as Cipla and Dr Reddy’s have entered the market with cost‑effective brigatinib tablets, prompting price pressure and broader patient access. Recent collaborations, including Takeda’s partnership with Roche for European market rollout and Cipla’s joint venture with a local Indian firm to expand production capacity, illustrate how M&A and strategic alliances are reshaping market dynamics. 'Takeda Pharmaceutical Company Limited', 'Natco Pharma Limited', 'Beacon Pharmaceuticals PLC', 'Hetero Labs Limited', 'Dr. Reddy's Laboratories Ltd.', 'Zydus Lifesciences Limited', 'MSN Laboratories Pvt. Ltd.', 'Laurus Labs Limited', 'Cipla Limited', 'Sun Pharmaceutical Industries Limited', 'Aurobindo Pharma Limited', 'Intas Pharmaceuticals Ltd.', 'Lupin Limited', 'Teva Pharmaceutical Industries Ltd.', 'Accord Healthcare Limited', 'Sandoz Group AG', 'Alvogen, Inc.', 'Apotex Inc.', 'Torrent Pharmaceuticals Ltd.', 'Macleods Pharmaceuticals Ltd.'
The approval of brigatinib for additional ALK‑positive and ROS1‑positive non‑small cell lung cancer indications expands its therapeutic scope, prompting oncologists to adopt it earlier in treatment pathways. This broader label drives higher prescribing rates as clinicians seek options that overcome resistance mechanisms. Increased use across hospitals, specialty pharmacies, and outpatient clinics fuels market demand, while heightened awareness campaigns by pharmaceutical partners reinforce confidence among prescribers, supporting sustained growth. Furthermore, patient advocacy groups emphasize the drug’s favorable safety profile, which further encourages its integration into standard care protocols.
Precision Oncology Integration: The adoption of comprehensive genomic profiling is reshaping prescribing patterns for brigatinib, as clinicians prioritize therapies aligned with specific ALK and ROS1 mutations. This shift drives demand for companion diagnostics and fosters collaborations between pharmaceutical firms and diagnostic providers. As treatment algorithms become increasingly mutation‑driven, healthcare systems are investing in data infrastructure to support real‑time decision making, thereby accelerating patient access to targeted brigatinib regimens and reinforcing its position within personalized lung cancer care pathways globally today.
Why does North America Dominate the Global Brigatinib Tablet Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
